Shares of Novartis NVS decreased 1.6% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 7.80% year over year to $1.52, which beat the estimate of $1.45.
Revenue of $12,259,000,000 rose by 0.71% year over year, which missed the estimate of $12,530,000,000.
Outlook
Novartis hasn't issued any earnings guidance for the time being.
Novartis hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Oct 27, 2020
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/3soac2di
Price Action
Company's 52-week high was at $99.84
52-week low: $69.18
Price action over last quarter: down 4.24%
Company Profile
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.